BioCentury
ARTICLE | Company News

I-Mab, Bio-Cancer partner to advance biotherapeies

February 8, 2019 1:46 AM UTC

I-Mab Biopharma (Shanghai, China) and Bio-Cancer Treatment International Ltd. (Hong Kong, China) partnered to establish a translational medicine lab in Hong Kong and implement an arginine depletion therapy and biomarker study.

The translational lab will study biomarkers for Bio-Cancer's lead drug candidate, BCT-100, and assets in I-Mab's pipeline. The study will explore biotherapeutics and biomarkers based on arginine metabolism in human malignancies and autoimmune disorders...